Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results

Friday, March 23, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

LEXINGTON, Mass., March 22, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology

company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, will issue financial results for the year ended December 31, 2017, on Thursday,
March 29, 2018
, prior to the market open.

Aldeyra will hold a conference call on Thursday, March 29, 2018, at 8:00 a.m. EDT to discuss the results.  The dial-in numbers are 1-877-266-8979 for domestic callers and 1-412-317-5231 for international callers.  A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com. 

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

About Aldeyra TherapeuticsAldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with inflammatory diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. Aldeyra is leveraging its experience in ocular inflammation to develop other product candidates for systemic inflammatory disease. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Corporate Contact:  Stephen Tulipano  Aldeyra Therapeutics, Inc.  Tel: +1 781-761-4904 ext. 205   stulipano@aldeyra.com

Investor Contact:  Chris Brinzey  Westwicke Partners  Tel: 339-970-2843  Chris.brinzey@westwicke.com

Media Contact:Cammy Duong  MacDougall Biomedical Communications   781-591-3443  cduong@macbiocom.com

 

Cision View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-full-year-2017-financial-results-300618473.html

SOURCE Aldeyra Therapeutics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store